Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Recipient : AffaMed Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In pre-clinical studies, AM712 (ASKG712) demonstrated robust efficacy, good ocular pharmacokinetics, and the desired safety profile supporting clinical exploration. AM712 is a novel bispecific biologic molecule specifically designed for ocular use.
Brand Name : AM712
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 30, 2022
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : AffaMed Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Single-domain Antibody
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : GenScript ProBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The single-domain antibodies involved in this license agreement will be paired with AskGene's proprietary next-generation cytokine therapeutics for cancer immunotherapy and other applications.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 26, 2021
Lead Product(s) : Single-domain Antibody
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : GenScript ProBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?